Biotech ETF Surges On Positive Trump Comments

donald trump
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +2.84% one-day return and outperforming the wider markets by a total of 2.85 percentage points.
NASDAQ:IBB January 31, 2017 5:51pm

BioShares Biotech Clinical Trials Fund, Up 5%, Is Today’s Top Performing ETF

biotech-white-pills
The BioShares Biotechnology Clinical Trials Fund (BBC) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a +5.03% one-day return and outperforming the wider markets by a total of 5.04 percentage points.
NASDAQ:BBC

Pfizer Provides Tepid Outlook As Q4 Results Miss Expectations

pfizer-pfe-logo
From StockNews.com: Pfizer Inc. (NYSE:PFE) early Tuesday posted disappointing fourth quarter results and offered a tepid outlook, amid weakening demand for some of its key drugs.
NYSE:PFE

Can Biotech ETFs Survive A Trump Presidency?

biotech-medical-pills
From Zacks: Biotech stocks have been under intense pressure for more than a year now with sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario weighing on the sector.
NASDAQ:IBB January 28, 2017 9:37am

AbbVie Issues In-Line Outlook Following Mixed Q4 Earnings

abbvie-logo
From StockNews.com: AbbVie Inc (NYSE:ABBV) early Friday posted mixed fourth quarter earnings results and issued a 2017 forecast that was in-line with Wall Street expectations.
NYSE:ABBV January 27, 2017 8:19am

Bristol-Myers Slashes Outlook As Q4 Profit Misses The Mark

BristolMyersSquibb-Co-logo
From StockNews.com: Bristol-Myers Squibb Co (NYSE:BMY) early Thursday posted mixed fourth quarter earnins reuslts and lowered its 2017 outlook, amid fears of regulators capping drug prices.
NYSE:BMY January 26, 2017 8:09am

Biogen Shares Down After Q4 Earnings, 2017 Weak Outlook

biogen-biib-logo
From StockNews.com: Biogen Inc (NASDAQ:BIIB) early Thursday posted mixed fourth quarter earnings results and offered a tepid 2017 outlook that sent its shares plunging.
NASDAQ:BIIB

Biotech Lags Again, IBB Closes Down Nearly 1% To Trail All ETFs

biotech-dna
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.94% one-day return and trailing the wider markets by a total of 0.68 percentage points.
NASDAQ:IBB January 24, 2017 7:19am

Bristol-Myers Collapse Was Predicted By These Technical Patterns

BristolMyersSquibb-Co-logo
From Corey Rosenbloom: If you’ve ever wondered why we chart momentum and volume along with price, BMY tells us why. On Friday, shares literally collapsed back to the lows, down from the prior swing highs.
NYSE:BMY January 22, 2017 8:12am

IHE Posted The Biggest Loss Of All ETFs Today, Down 1%

Image of multicolor pills in blister pack
The iShares Dow Jones US Pharmaceuticals Index Fund (IHE) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.98% one-day return and trailing the wider markets by a total of 1.35 percentage points.
NYSE:IHE January 20, 2017 6:05pm

So Much For The Bounce: IBB, Down 0.85%, Is Today’s Biggest ETF Loser

biotech-medical-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.84% one-day return and trailing the wider markets by a total of 0.47 percentage points.
NASDAQ:IBB January 19, 2017 6:53pm

IBB Bounces Back, Is Today’s Best Performing ETF On A Dollar Basis

biotech-white-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +0.83% one-day return and outperforming the wider markets by a total of 0.61 percentage points.
NASDAQ:IBB January 18, 2017 5:08pm

Eli Lilly Buys Migraine Treatment Specialist CoLucid For $960M In Cash

eli-lilly-lly-logo
From StockNews.com: Eli Lilly and Co (NYSE:LLY) will acquire CoLucid Pharmaceuticals, a maker of a cutting edge migraine headache treatment, for $960 million, the two companies announced this morning.
ETF BASIC NEWS

The IBB Trailed All Major ETFs Today, With A Nearly 2% Drop

Arrow down
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -1.96% one-day return and trailing the wider markets by a total of 1.61 percentage points.
NASDAQ:IBB January 17, 2017 5:16pm

Recommended for You

Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories